FDA Head Calls for Inspector General Investigation of Aduhelm Approval

In a surprise move, Janet Woodcock, acting commissioner of the U.S. Food and Drug Administration (FDA), asked the independent Office of the Inspector General to investigate how the FDA and representatives of Biogen interacted prior to the FDA’s approval of the company’s Aduhelm (aducanumab) for Alzheimer’s disease.